AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21627396 — intervention group
Group type: COMPARATOR
Intervention: Conventional PIVC (BD Insyte Autoguard Shielded IV Catheter)
Number of subjects: 234
Study 21627396 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC-BC with venous compression
Number of subjects: 234
Study 21627396 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC-BC without venous compression
Number of subjects: 234
Study 21627396 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVC with blood control (PIVC-BC)
Number of subjects: 234
Study 21627396 — intervention group
Group type: COMPARATOR
Intervention: Conventional PIVC
Number of subjects: 234
Study 19466288 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 240
Study 19466288 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal epidural anesthesia (CSE)
Number of subjects: 240
Study 16304673 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 632
Study 15450647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined counseling and case management behavioral intervention using motivational interviewing strategies
Number of subjects: 440
Study 15450647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 440
Study 15450647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined counseling and case management behavioral intervention
Number of subjects: 440
Study 11355917 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening using faecal occult blood tests, endoscopic methods, and different tumour markers; specific dosages and durations not mentioned.
Number of subjects: 0
Study 11355917 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention by dietary intervention and drugs; specific details not mentioned.
Number of subjects: 0
Study 11355917 — intervention group
Group type: EXPERIMENTAL
Intervention: Different screening methods in populations with varying risk of colorectal cancer; specific methods not detailed.
Number of subjects: 0
Study 9746023 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessed resuscitation
Number of subjects: 25
Study 9746023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not allowed to witness resuscitation)
Number of subjects: 25
Study 11548229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Hyalgan, Fidia SpA, Italy)
Number of subjects: 12
Study 11548229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11548229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 12
Study 3061425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (mean dose 11.5 mg over 3.4 min)
Number of subjects: 102
Study 3061425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (mean dose 6.0 mg over 3.3 min)
Number of subjects: 102
Study 30425347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 21 (FGF-21) levels within the highest tertile
Number of subjects: 626
Study 27533263 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual orientation concerning the patients' conditions
Number of subjects: 210
Study 27533263 — intervention group
Group type: COMPARATOR
Intervention: Routine orientation of the unit
Number of subjects: 210
Study 25605544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (rhEPO) 33,000 IU administered at days 1-3
Number of subjects: 30
Study 25605544 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 1,000 mg per day for 3 days + 0.9% normal saline (placebo)
Number of subjects: 30
Study 23128366 — intervention group
Group type: EXPERIMENTAL
Intervention: Web communication
Number of subjects: 904
Study 23128366 — intervention group
Group type: EXPERIMENTAL
Intervention: Print communication
Number of subjects: 904
Study 23128366 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 904
Study 21168115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 120
Study 21168115 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 120
Study 18685477 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict resolution training program
Number of subjects: 0
Study 18685477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12452944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-alpha therapy (daily 9 MU for 4 weeks, then 6 MU for weeks 5-8, 3 MU for weeks 9-12, and 1.5 MU for weeks 13-48) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Number of subjects: 30
Study 12452944 — intervention group
Group type: COMPARATOR
Intervention: Standard-dosage interferon-alpha therapy (thrice weekly 6 MU for 12 weeks, then 3 MU for 36 weeks) with ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 weeks
Number of subjects: 30
Study 9605002 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg intravenously, 5 minutes before chemotherapy)
Number of subjects: 50
Study 9605002 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg intravenously, 5 minutes before chemotherapy) with additional doses if vomiting occurs
Number of subjects: 50
Study 8583516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care day treatment program including drug free contingent work therapy and housing
Number of subjects: 131
Study 8583516 — intervention group
Group type: COMPARATOR
Intervention: Usual Care outpatient program
Number of subjects: 131
Study 8583516 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects across four evaluation points
Number of subjects: 131
Study 2666339 — intervention group
Group type: EXPERIMENTAL
Intervention: RHEZ6 regimen (4 drug, 6 months: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide)
Number of subjects: 288
Study 2666339 — intervention group
Group type: COMPARATOR
Intervention: RHE9 regimen (3 drug, 9 months: Rifampicin, Isoniazid, Ethambutol)
Number of subjects: 288
Study 2666339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 288
Study 2666339 — intervention group
Group type: EXPERIMENTAL
Intervention: RHEZ6 regimen
Number of subjects: 288
Study 140084 — intervention group
Group type: EXPERIMENTAL
Intervention: bufexamac cream
Number of subjects: 193
Study 140084 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide cream
Number of subjects: 193
Study 140084 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 193
Study 140084 — intervention group
Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 193
Study 28869478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 0
Study 28869478 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 0
Study 28869478 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 25654175 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive quality improvement interventions (education, generic protocol, order set, local champions)
Number of subjects: 934
Study 25654175 — intervention group
Group type: EXPERIMENTAL
Intervention: Active quality improvement interventions (nurse specialist, monthly audit-feedback, network educational events, internet blog)
Number of subjects: 934
Study 25654175 — intervention group
Group type: COMPARATOR
Intervention: Baseline standard of care (no intervention)
Number of subjects: 934
Study 25654175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival to hospital discharge
Number of subjects: 934
Study 24354113 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate
Number of subjects: 107
Study 24354113 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 107
Study 22480093 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg thrice daily
Number of subjects: 80
Study 22480093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg thrice daily
Number of subjects: 80
Study 19523083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 1534
Study 19523083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in obese children and adolescents
Number of subjects: 1534
Study 16733916 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol valerate (E2 V) 1 mg/d + medroxyprogesterone acetate (MPA) 2 mg/d
Number of subjects: 136
Study 16733916 — intervention group
Group type: EXPERIMENTAL
Intervention: conjugated equine estrogen 0.45 mg/d + MPA 2 mg/d
Number of subjects: 136
Study 16733916 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 1.25 mg/d
Number of subjects: 136
Study 16733916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese formulated herbs product (Kuntai) 4# tid
Number of subjects: 136
Study 14985216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytic acid (1.49 mmol) added to test meal
Number of subjects: 9
Study 14985216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytic acid (0.75 mmol) added to test meal
Number of subjects: 9
Study 14985216 — intervention group
Group type: COMPARATOR
Intervention: No added phytic acid
Number of subjects: 9
Study 11307804 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C69931MX at 2 microg/kg/min for 21 h (Part 1)
Number of subjects: 39
Study 11307804 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C69931MX at up to 69 h (Part 2)
Number of subjects: 39
Study 11307804 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C69931MX at 4 microg/kg/min for up to 69 h (Part 3)
Number of subjects: 39
Study 11307804 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C69931MX (all parts)
Number of subjects: 39
Study 9150774 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion, 80 micrograms.kg-1.min-1 during surgery and 40 micrograms.kg-1.min-1 for 3 hours postoperatively
Number of subjects: 43
Study 9150774 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during surgery
Number of subjects: 43
Study 9150774 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion
Number of subjects: 43
Study 9150774 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 43
Study 7962388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero cell co-culture system
Number of subjects: 0
Study 7962388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero cell monolayer for 24 hours
Number of subjects: 0
Study 29543076 — intervention group
Group type: EXPERIMENTAL
Intervention: 3° × 180° COD
Number of subjects: 0
Study 29543076 — intervention group
Group type: COMPARATOR
Intervention: Collision workloads
Number of subjects: 0
Study 29543076 — intervention group
Group type: COMPARATOR
Intervention: Total distance per minute
Number of subjects: 0
Study 29889390 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with proton pump inhibitors (PPIs)
Number of subjects: 131
Study 29889390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with PPI + ursodeoxycholic acid (UDCA)
Number of subjects: 131
Study 29889390 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal body weight)
Number of subjects: 131
Study 24867408 — intervention group
Group type: COMPARATOR
Intervention: 0 g bLF daily for 1 year
Number of subjects: 0
Study 24867408 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g bLF daily for 1 year
Number of subjects: 0
Study 24867408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g bLF daily for 1 year
Number of subjects: 0
Study 22302533 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning (LIC) prior to MIE
Number of subjects: 16
Study 22302533 — intervention group
Group type: COMPARATOR
Intervention: MIE without laparoscopic ischemic conditioning (N)
Number of subjects: 16
Study 20138189 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (150 microg) + hepatitis B vaccine (20 microg)
Number of subjects: 100
Study 20138189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (40 microg) only
Number of subjects: 100
Study 20138189 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (20 microg) each time
Number of subjects: 100
Study 19457618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (single dose administered intranasally)
Number of subjects: 26
Study 19457618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose administered intranasally)
Number of subjects: 26
Study 16794364 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide 30 mg
Number of subjects: 60
Study 16794364 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 14631473 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 5886
Study 14631473 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased waist circumference
Number of subjects: 5886
Study 14631473 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased waist-to-hip ratio
Number of subjects: 5886
Study 10845898 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT)
Number of subjects: 541
Study 10845898 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 541
Study 9338955 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive longitudinal study
Number of subjects: 0
Study 9338955 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected prevention study
Number of subjects: 0
Study 9338955 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated prevention study
Number of subjects: 0
Study 7679836 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506/prednisone
Number of subjects: 125
Study 7679836 — intervention group
Group type: COMPARATOR
Intervention: FK 506/azathioprine/prednisone
Number of subjects: 125
Study 3529370 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol) for 8 weeks
Number of subjects: 28
Study 29887289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (N2O) inhalation (50% for 30 minutes)
Number of subjects: 60
Study 29887289 — intervention group
Group type: COMPARATOR
Intervention: Retrieval with negative PE
Number of subjects: 60
Study 29887289 — intervention group
Group type: COMPARATOR
Intervention: Retrieval with no PE
Number of subjects: 60
Study 29887289 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol memory retrieval with PE
Number of subjects: 60
Study 26818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC)
Number of subjects: 135
Study 26818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin (FL)
Number of subjects: 135
Study 26818420 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A12 (FS)
Number of subjects: 135
Study 26818420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) and fecal lactoferrin (FL)
Number of subjects: 135
Study 26818420 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and Crohn's Disease Activity Index (CDAI)
Number of subjects: 135
Study 24836523 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-specific dose reduction (OSDR) and attenuation-based tube potential selection (ATPS)
Number of subjects: 70
Study 24836523 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (control group)
Number of subjects: 70
Study 22342007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric Acri.Smart 36A IOL
Number of subjects: 152
Study 22342007 — intervention group
Group type: COMPARATOR
Intervention: Spherically neutral Akreos MI60 IOL
Number of subjects: 152
Study 22342007 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOLs
Number of subjects: 152
Study 22342007 — intervention group
Group type: COMPARATOR
Intervention: Spherically neutral IOLs
Number of subjects: 152
Study 22342007 — intervention group
Group type: COMPARATOR
Intervention: Negatively aspheric IOLs (asphericity -0.17 μm)
Number of subjects: 152
Study 20195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling in value-based medicine (VBM)
Number of subjects: 0
Study 20195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic modeling
Number of subjects: 0
Study 20195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Model validation
Number of subjects: 0
Study 19173919 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-endostatin plus NP chemotherapy
Number of subjects: 57
Study 19173919 — intervention group
Group type: COMPARATOR
Intervention: NP alone
Number of subjects: 57
Study 15920685 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LR)
Number of subjects: 83
Study 15920685 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 83
Study 12051882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin 8 mg/m², Doxorubicin 40 mg/m², Cisplatin 60 mg/m² (MAP chemotherapy)
Number of subjects: 37
Study 10063926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 infusion (30 microg/hr)
Number of subjects: 14
Study 7747698 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave acute myocardial infarction (AMI)
Number of subjects: 1473
Study 7747698 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of prior coronary angioplasty
Number of subjects: 1473
Study 7747698 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of pain >= 60 minutes
Number of subjects: 1473
Study 7747698 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment deviation on the qualifying electrocardiogram
Number of subjects: 1473
Study 7747698 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent-onset angina
Number of subjects: 1473
Study 7747698 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for non-Q-wave AMI
Number of subjects: 1473
Study 2139241 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method of treatment
Number of subjects: 100
Study 2139241 — intervention group
Group type: COMPARATOR
Intervention: Patient education in 'mini back school'
Number of subjects: 100
Study 6105436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 214
Study 30734388 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave-CAIPI (9-fold acceleration)
Number of subjects: 30
Study 30734388 — intervention group
Group type: COMPARATOR
Intervention: GRAPPA (2-4 fold acceleration)
Number of subjects: 30
Study 27658762 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 20
Study 27658762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25416739 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional upper extremity task-specific training (2250 repetitions of simulated feeding with nondominant hand over 3 days)
Number of subjects: 50
Study 25416739 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 50
Study 23851069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin at doses of 0.3mg and above
Number of subjects: 36
Study 23851069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin at doses of 0.1mg and above
Number of subjects: 36
Study 23851069 — intervention group
Group type: EXPERIMENTAL
Intervention: New OEL for dapagliflozin
Number of subjects: 36
Study 21415052 — intervention group
Group type: EXPERIMENTAL
Intervention: initial combination therapy
Number of subjects: 508
Study 21415052 — intervention group
Group type: COMPARATOR
Intervention: sequential monotherapy
Number of subjects: 508
Study 21415052 — intervention group
Group type: COMPARATOR
Intervention: step-up combination therapy
Number of subjects: 508
Study 21415052 — intervention group
Group type: COMPARATOR
Intervention: initial combination with prednisone
Number of subjects: 508
Study 21415052 — intervention group
Group type: COMPARATOR
Intervention: initial combination with infliximab
Number of subjects: 508
Study 19105889 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg vitamin D(2)
Number of subjects: 25
Study 19105889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17339864 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min before ethanol (0.6 gm/kg)
Number of subjects: 20
Study 17339864 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate (MPH) 0.3 mg/kg administered orally 30 min after ethanol (0.6 gm/kg)
Number of subjects: 20
Study 17339864 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.6 gm/kg)
Number of subjects: 20
Study 17339864 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 20
Study 12646332 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate hydrochloride (LAAM)
Number of subjects: 163
Study 10967897 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP treatment (Group L)
Number of subjects: 102
Study 9366458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (3 microg/kg) administered over 2 min
Number of subjects: 30
Study 9366458 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxant (Pancuronium 0.1 mg/kg) administered after sufentanil
Number of subjects: 30
Study 8378947 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit (n = 124)
Number of subjects: 245
Study 8378947 — intervention group
Group type: COMPARATOR
Intervention: General medical wards (n = 121)
Number of subjects: 245
Study 3460327 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan (group 1: n = 11)
Number of subjects: 21
Study 3460327 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (VP16‐213 with cytosine arabinoside and doxorubicin) (group 2: n = 10)
Number of subjects: 21
Study 31729895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual arousal condition
Number of subjects: 115
Study 31729895 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 115
Study 28183863 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-Intensity with Blood Flow Restriction (LI+BFR) during leg-press
Number of subjects: 0
Study 28183863 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-Intensity with Blood Flow Restriction (LI+BFR) during treadmill exercise
Number of subjects: 0
Study 25586270 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion (Hb < 9.7 g/dL; < 6 mmol/L)
Number of subjects: 284
Study 25586270 — intervention group
Group type: COMPARATOR
Intervention: Liberal RBC transfusion (Hb < 11.3 g/dL; < 7 mmol/L)
Number of subjects: 284